eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.

The eukaryotic translation initiation factor 3a (eIF3a) is one of the core subunits of the translation initiation complex eIF3, responsible for ribosomal subunit joining and mRNA recruitment to the ribosome. Our previous study identified that it was correlated with platinum response in lung cancer. The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27(Kip1). Immunohistochemistry and western blot was used to determine the expression of eIF3a in 126 human ovarian cancer tissues followed by association analysis of eIF3a expression with patient's response and survival. Ectopic over-expression and RNA interference knockdown of eIF3a were carried out in A2780/cisplatin (DDP) and its parental A2780 cells, respectively, to determine the effect of altered eIF3a expression on cellular response to cisplatin by employing MTT assay. Western Blot analyses were also carried out to determine the regulation of eIF3a on XPC and p27(Kip1). eIF3a expression was associated with response of ovarian cancer patients to DDP-based chemotherapy and their survival. Overexpression and knockdown of eIF3a increased and decreased the cellular response to cisplatin in A2780/DDP and A2780 cells, respectively. In addition, XPC and p27(Kip1) were down regulated by eIF3a. eIF3a improves ovarian cancer patients' response to DDP-based chemotherapy via down regulating XPC and p27(Kip1).
AuthorsYu Zhang, Jing-Jing Yu, Yan Tian, Zheng-Zheng Li, Cai-Yi Zhang, Shu-Fen Zhang, Lan-Qin Cao, Yi Zhang, Chen-Yue Qian, Wei Zhang, Hong-Hao Zhou, Ji-Ye Yin, Zhao-Qian Liu
JournalOncotarget (Oncotarget) Vol. 6 Issue 28 Pg. 25441-51 (Sep 22 2015) ISSN: 1949-2553 [Electronic] United States
PMID26213845 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CDKN1B protein, human
  • DNA-Binding Proteins
  • EIF3A protein, human
  • Eukaryotic Initiation Factor-3
  • Cyclin-Dependent Kinase Inhibitor p27
  • XPC protein, human
  • Cisplatin
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cell Line, Tumor
  • Cisplatin (therapeutic use)
  • Cyclin-Dependent Kinase Inhibitor p27 (genetics, metabolism)
  • DNA-Binding Proteins (genetics, metabolism)
  • Dose-Response Relationship, Drug
  • Eukaryotic Initiation Factor-3 (genetics, metabolism)
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Ovarian Neoplasms (drug therapy, genetics, metabolism, mortality, pathology)
  • Proportional Hazards Models
  • RNA Interference
  • Signal Transduction (drug effects)
  • Time Factors
  • Transfection
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: